N
NeuroVasc Technologies
Making a mechanical thrombectomy device in order to reduce the risk of death
About NeuroVasc Technologies
NeuroVasc Technologies Inc. is a medical device startup focused on developing advanced solutions for the treatment of acute ischemic stroke. The company operates in the medical technology sector, specifically targeting the revascularization of the brain during stroke events. Its flagship product, the Versi Mechanical Thrombectomy System, is designed to remove blood clots from the brain's blood vessels, thereby restoring blood flow and minimizing stroke-related damage. The system can be used in conjunction with thrombolytic drugs and aspiration devices, enhancing its effectiveness in treating large vessel occlusions (LVO).
NeuroVasc Technologies serves healthcare providers, including hospitals and specialized stroke centers, that require cutting-edge tools to improve patient outcomes. The company operates in a highly specialized market, addressing the critical need for effective stroke interventions. Its business model revolves around the development, manufacturing, and sale of its thrombectomy system, generating revenue through direct sales and partnerships with medical institutions.
The company makes money by selling its medical devices to healthcare facilities and through potential collaborations with pharmaceutical companies for combined treatment solutions. NeuroVasc Technologies aims to reduce the long-term disability and mortality rates associated with strokes, thereby addressing a significant global health issue.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Irvine, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 46.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Risk Management, Surgery, Neurology, Hard Tech, DT and LS, science-based, stroke
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Feb 2020 | $34M | $136M | Weigao Group | ↗ |
| SERIES B✓Equity / VC | May 2018 | $6.3M | $25M | ShangBay Capital | — |
Growth signals
Latest recorded traffic for NeuroVasc Technologies is 1.6K monthly website visits, up 14.3% over the last three months. NeuroVasc Technologies's team grew 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
ShangBay Capital
Series B and later1 investor entered at this stage
Weigao Group
Other known investors2 additional known investors
- SCSVE Capital
SVE Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroVasc Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroVasc Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.